BIOMAT Database Logo BIOMAT Database Logo

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. 1997

J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA.

HER-2/neu expression has been established as a prognostic factor in breast and other cancers. In prostate cancer (PC), a similar predictive role has been hindered by variable immunohistochemical (IHC) results. The authors studied DNA amplification of the HER-2/neu gene on 4-microm sections obtained from 62 formalin-fixed, paraffin-embedded PCs by fluorescence in situ hybridization (FISH). The results were compared with HER-2/neu protein expression as determined by IHC and correlated by logistic regression analysis with Gleason tumor grade, DNA ploidy, serum prostate specific antigen (PSA), and pathological stage. The HER-2/neu gene was localized using the Oncor (Gaithersburg, MD) digoxigenin-labeled unique sequence probe. Amplified PCs had at least 20 malignant cells, with 5 or more copies of the sequence. Amplification of HER-2/neu correlated with Gleason score (P = .0001). The mean Gleason score of unamplified tumors was 5.7 and that of amplified tumors was 7.5. Nondiploid tumors had a significantly greater rate of HER-2/neu amplification compared with diploid tumors (P = .0003). Of the 62 cases evaluated by IHC and FISH, 18 cases (29%) were overexpressed by IHC, and 27 cases (44%) were amplified by FISH. A trend for similar HER-2/neu status in each PC by the two methods did not reach statistical significance (P = .23). HER-2/neu amplification by FISH was associated with advanced pathological stage; however, this relationship reached only near-statistical significance (P = .06). There was no correlation of HER-2/neu amplification by FISH with patient age or preoperative serum PSA levels. The authors conclude that HER-2/neu gene amplification status can be determined by FISH on archival prostate cancer specimens, significantly correlates with high tumor grade and nondiploid DNA content, and is more frequently encountered in tumors with advanced pathological stage. Also, FISH is more sensitive than IHC for detection of abnormalities in the HER-2/neu gene, and further studies should be undertaken to determine whether a FISH-based HER-2/neu detection method may prove of importance in the prediction of prognosis and planning of therapy in prostate cancer patients.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
January 2001, Cancer journal (Sudbury, Mass.),
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
June 1999, Experimental and molecular pathology,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.
September 1997, The American journal of pathology,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
October 2010, Anticancer research,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
April 1999, International journal of oncology,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Immunohistochemical her-2/ Neu expression with gene amplification by fluorescence in situ hybridization for assessment in breast carcinomas.
December 2007, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
August 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
January 2007, Journal of cutaneous pathology,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
August 2018, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
J S Ross, and C Sheehan, and A M Hayner-Buchan, and R A Ambros, and B V Kallakury, and R Kaufman, and H A Fisher, and P J Muraca
HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.
September 2002, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!